Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-858-4 | CAS number: 12037-47-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Dermal (OECD 402), rat: LD50 > 2000 mg/kg bw (limit test)
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, 97633 Sulzfeld, Germany
- Age at study initiation: 8-10 wks (males), 12-14 wks (females)
- Weight at study initiation: 235-247 g (males), 215-238 wks (females)
- Housing: individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (lot 261111)
- Diet (ad libitum): Altromin 1324 (lot 0715)
- Water (ad libitum): tap water, sulphur acidified to a pH of approximately 2.8
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- % coverage: 10% of the total body surface
- Type of wrap if used: The test item was held in contact with the skin by a dressing throughout a 24-h period. The dressing consisted of a gauze-dressing and non-irritating tape and was fixed with an additional dressing in a suitable manner.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): yes
- Time after start of exposure: at the end of the 24 h exposure period the residual test item was removed using aqua ad injectionem
- For solids, paste formed: yes, the test substance was moistened with aqua ad injectionem - Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: cageside observations were done several times on the days of dosing and once a day until the end of the observation period. Observations included general symptoms, changes in the skin and fur, eyes, and mucous membranes. Also changes in respiratory, circulatory, autonomic and centrals nervous system and somatomotor activity and behaviour pattern were examined. Attention was directed to observations of tremors convulsions, salivation, diarrhea, lethargy, sleep and coma. Weighing was done on day 1 (prior to application) and on days 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, other: primary skin irritation was assessed using the scoring system of Draize - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred during the study period.
- Clinical signs:
- other: No clinical signs of toxicity were observed up to the end of the 14-day observation period.
- Gross pathology:
- With the exception of acute injection of blood vessels in the abdominal region, which was due to the euthanasia injection, no specific gross pathological changes were recorded for any animal.
- Other findings:
- - Other observations: Erythema grade 1 was observed in 1 of 5 female animals on Days 2 and 3 after start of the application. Scratches and eschar were observed in all male and female animals. All signs of irritation were reversible within the observation period. Edema was not observed (see Tables 2 and 3).
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- CLP: not classified
DSD: not classified
Reference
Table 1: Body weight development (in g and %)
Sex |
Day 1 (g) |
Day 8 (g) |
Day 15 (g) |
Day 1-15 (%) |
male |
238 |
260 |
300 |
26 |
male |
243 |
257 |
287 |
18 |
male |
247 |
266 |
303 |
23 |
male |
238 |
256 |
280 |
18 |
male |
235 |
244 |
279 |
19 |
female |
238 |
239 |
255 |
7 |
female |
215 |
220 |
227 |
6 |
female |
220 |
216 |
229 |
4 |
female |
217 |
215 |
235 |
8 |
female |
226 |
223 |
230 |
2 |
Table 2: Skin irritation: Individual data - Males
Day after start application |
Animal No. 21 |
Animal No. 22 |
Animal No. 23 |
Animal No. 24 |
Animal No. 25 |
|||||
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
|
Day 2 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 3 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s* |
Day 4 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
Day 5 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
(es, s)* |
0/0 |
es, s |
Day 6 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
(es, s)* |
0/0 |
es, s |
Day 7 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
Day 8 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
nsf |
0/0 |
nsf |
Day 9 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
nsf |
0/0 |
nsf |
Day 10 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 11 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 12 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 13 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 14 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 15 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Comments:
E = erythema, O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD Guideline 404 (Table 2, Draize scoring system)
es = eschar, s = scratches, s* = small scratches, (es, s)* = eschar and scratches on the edge of the application site; nsf = no specific finding
Table 3: Skin irritation: Individual data - Females
Day after start application |
Animal No. 26 |
Animal No. 27 |
Animal No. 28 |
Animal No. 29 |
Animal No. 30 |
|||||
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
|
Day 2 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 3 |
1/0 |
es, s* |
0/0 |
es, s |
0/0 |
es, s* |
0/0 |
es, s* |
0/0 |
s* |
Day 4 |
1/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
nsf |
Day 5 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
(es, s)* |
0/0 |
nsf |
Day 6 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
(es, s)* |
0/0 |
nsf |
Day 7 |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
nsf |
Day 8 |
0/0 |
nsf |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
nsf |
0/0 |
nsf |
Day 9 |
0/0 |
nsf |
0/0 |
es, s |
0/0 |
es, s |
0/0 |
nsf |
0/0 |
nsf |
Day 10 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 11 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 12 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 13 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 14 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Day 15 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Comments:
E = erythema, O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD Guideline 404 (Table 2, Draize scoring system)
es = eschar, s = scratches, s* = small scratches, (es, s)* = eschar and scratches on the edge of the application site; nsf = no specific finding
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The available information comprises an adequate and reliable study (Klimisch score 1), and is thus sufficient to fulfil the standard information requirements set out in Annex VII, 8.5, of Regulation (EC) No 1907/2006.
Additional information
Dermal
According to OECD 402, 2000 mg/kg bw of silicon orthophosphate was dermally applied to the intact skin of 5 male and 5 female rats each (BSL, 2012). The test substance was placed on a wet gauze patch and applied to the skin for 24 h under occlusive conditions. After the exposure period, the gauze patch was removed and the treated skin was rinsed with water. There were no deaths or signs of toxicity during the study. A slight weight loss was recorded for 3 out of 5 female animals during the first week, but all of the female animals showed weight gain during the second week. The male animals showed weight gain during the first and second week of the observation. With the exception of acute injection of blood vessels in the abdominal region, which was due to the euthanasia injection, no specific gross pathological changes were recorded for any animal. Erythema grade 1 was observed in 1 of 5 female animals 48 and 72 h after patch removal. This effect was fully reversible within 120 h after application of the test substance. Edema was not observed. Scratches and eschar were observed in all male and female animals from day 3 to day 9 at the latest. Hence, all signs of irritation were reversible within the observation period of 14 days. The LD50 of the test substance was > 2000 mg/kg bw.
Justification for selection of acute toxicity – oral endpoint
No study required since exposure of humans via inhalation is unlikely taking into the lack of exposure into consideration: Silicon orthophosphate is only imported as already included as extrudate into the matrix of a catalyst. The substance is therefore inert and inhalation can be excluded. Therfore and due to animal welfare, acute oral toxicity was not tested.
Justification for selection of acute toxicity – inhalation endpoint
No study required since exposure of humans via inhalation is unlikely taking into the lack of exposure into consideration: Silicon orthophosphate is only imported as already included as extrudate into the matrix of a catalyst. The substance is therefore inert and inhalation can be excluded. Therfore and due to animal welfare, acute inhalation toxicity was not tested.
Justification for selection of acute toxicity – dermal endpoint
Only one study available.
Justification for classification or non-classification
The available data on dermal acute toxicity of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008 or Directive 67/548/EEC, and are therefore conclusive but not sufficient for classification.
No data on acute oral and inhalation toxicity are available.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.